Veozah vs Combipatch / Climara Pro: Special Populations Head-to-Head

What Each Drug Actually Does in Your Body

These two treatment categories work through completely different mechanisms, which is exactly why the "right" choice shifts so much depending on your individual physiology.

Fezolinetant (Veozah) targets the neurokinin B signaling pathway in the hypothalamus. In menopause, declining estrogen unmasks the KNDy neuron circuit, which drives the thermoregulatory dysfunction that causes hot flashes. Fezolinetant blocks the neurokinin 3 receptor (NK3R), quieting that misfiring circuit without putting estrogen back into your system. The SKYLIGHT-1 trial published in The Lancet showed fezolinetant 45 mg reduced moderate-to-severe hot flash frequency by approximately 45% compared with placebo at week 12, with a mean reduction of roughly 2.5 fewer hot flashes per day.

Combination estrogen-progestin patches (Combipatch, Climara Pro) replace the estrogen your ovaries have stopped making. Estrogen directly resets the thermostat. The progestin component (norethindrone acetate in Combipatch, levonorgestrel in Climara Pro) protects the uterine lining from unopposed-estrogen stimulation. Because both patches deliver hormones transdermally, they bypass first-pass liver metabolism, which matters for clotting-factor production and triglyceride metabolism.

Why the Mechanism Gap Matters Clinically

Fezolinetant does one thing: reduce vasomotor symptoms. It does not improve vaginal dryness, does not protect bone density, and does not address genitourinary syndrome of menopause (GSM). The Menopause Society (formerly NAMS) 2023 position statement is explicit that estrogen-based therapy remains the most effective treatment for the full spectrum of menopausal symptoms and offers documented skeletal and cardiovascular benefits when started in women under 60 or within 10 years of menopause onset.

Combination patches address hot flashes, night sweats, GSM, bone turnover, and mood symptoms linked to estrogen withdrawal. The tradeoff is a hormonal mechanism with its associated risk profile.

Head-to-Head in Special Populations

This is where the comparison gets genuinely useful. No direct randomized trial has put fezolinetant against a combination patch in a single study. What follows synthesizes available trial data, pharmacology, and current guideline positions.

Women With Hormone-Sensitive Cancer History

This population is where fezolinetant's hormone-free mechanism changes everything.

Women with a personal history of estrogen receptor-positive (ER+) breast cancer face significant uncertainty with systemic estrogen, and most oncology guidelines advise against it. ACOG Practice Bulletin 126 on management of menopausal symptoms acknowledges that non-hormonal options are preferred after hormone-sensitive cancers. Fezolinetant carries no estrogenic activity. Its 2023 FDA label does not list hormone-sensitive cancer as a contraindication, and it was specifically studied in women who could not or chose not to use hormones.

Combination patches are generally avoided in this group. Oncologists routinely flag any systemic estrogen as potentially problematic for women on adjuvant aromatase inhibitors or tamoxifen, where reintroducing circulating estrogen runs counter to the treatment goal.

If you have a history of ER+ breast cancer and are suffering from severe hot flashes, fezolinetant is currently the only FDA-approved prescription option that does not involve estrogen. Data on fezolinetant in active cancer treatment is limited, and you need an oncology and menopause specialist conversation before starting.

Women With Cardiovascular Risk Factors

Both drugs have meaningful risk considerations here, and they differ in direction.

Transdermal estrogen avoids the hepatic first-pass effect that oral estrogen triggers. A 2004 publication in Menopause examining continuous combined transdermal HRT confirmed that transdermal delivery does not significantly increase C-reactive protein, sex hormone-binding globulin, or triglycerides, unlike oral formulations. This pharmacokinetic advantage is why transdermal routes are often preferred in women with elevated triglycerides or hypertension.

Veozah's cardiovascular footprint is different. It does not affect lipids or clotting factors, but it also carries no documented cardioprotective effect. The SKYLIGHT trials did not enroll enough women with significant cardiovascular disease to draw conclusions about safety in that population.

Women under 60 who are within 10 years of their final menstrual period and who have no personal history of cardiovascular disease are generally considered good candidates for transdermal hormone therapy. Women with a history of deep vein thrombosis or stroke should avoid combination patches; fezolinetant becomes a reasonable alternative for hot flash control in that group.

Women With PCOS

PCOS creates a specific hormonal environment that complicates both options. Many women with PCOS have residual androgen excess and insulin resistance that persists into perimenopause and early postmenopause. Here is a framework for thinking through the choice:

Fezolinetant in PCOS: No PCOS-specific trial data exists. Because PCOS involves chronic low-grade LH pulse dysregulation (also a KNDy-mediated process), there is biologic plausibility that NK3R blockade could affect LH secretion patterns. This has not been studied prospectively in PCOS populations, and extrapolating from menopause data should be done cautiously.

Combination patches in PCOS: The progestin component matters here. Levonorgestrel (Climara Pro) has androgenic activity and may worsen acne, hirsutism, or insulin sensitivity in women with residual androgen sensitivity. Norethindrone acetate (Combipatch) is also mildly androgenic. Neither patch provides the metabolic benefit of a low-androgenic or anti-androgenic progestin. If a woman with PCOS needs HRT, an estradiol patch paired with micronized progesterone (Prometrium) is often a more metabolically favorable combination, though that is outside the scope of this direct comparison.

Women With Elevated Liver Enzymes or Hepatic Conditions

Veozah requires hepatic monitoring. The FDA label for fezolinetant lists hepatotoxicity as a serious warning. Liver enzyme testing is required before starting and periodically during treatment. Women with baseline ALT or AST greater than twice the upper limit of normal should not use fezolinetant.

Combination transdermal patches avoid the hepatic first-pass effect and are generally safer for women with mild-to-moderate liver conditions compared with oral estrogen. However, active liver disease remains a contraindication for all hormone therapy forms. Women with controlled non-alcoholic fatty liver disease who need menopause symptom relief may actually tolerate a transdermal estrogen patch better than fezolinetant if liver enzymes are already elevated.

Perimenopausal Women (Still Having Irregular Periods)

This is a population where the two drugs diverge considerably in practical terms.

Fezolinetant is FDA-approved for postmenopausal vasomotor symptoms. Perimenopause is technically off-label. The KNDy pathway is still disrupted in perimenopause, so the biology supports use, but the trial data is concentrated in confirmed postmenopausal women.

Combination patches containing a progestin are a reasonable choice in perimenopause for women who also need contraception, though the doses in Combipatch and Climara Pro are sub-contraceptive. A woman in perimenopause who needs both symptom relief and contraception needs a separate contraception discussion with her clinician.

Women Who Have Had a Hysterectomy

If you no longer have a uterus, you do not need the progestin component of a combination patch. Estrogen-only transdermal therapy (such as a Climara single-hormone patch) carries a cleaner risk profile without the progestin-associated concerns around breast tissue and mood. Combination patches in this population add progestin without adding uterine protection benefit. Fezolinetant remains an option if estrogen is contraindicated, but for most post-hysterectomy women without contraindications, estrogen-only transdermal therapy is the simplest, most evidence-backed path.

Pregnancy, Lactation, and Contraception Requirements

Both drug classes are contraindicated in pregnancy. This section applies especially to perimenopausal women, who can still ovulate.

Fezolinetant (Veozah)

The fezolinetant FDA prescribing information advises that the drug is not for use in pregnant women. Animal reproductive studies showed fetal harm at supratherapeutic doses. Human pregnancy data is essentially absent because the trials excluded pregnant women. If you are in perimenopause and could still conceive, you need reliable contraception while taking Veozah.

Lactation data is also absent. It is unknown whether fezolinetant or its metabolites transfer into breast milk. Given the lack of data, the FDA label recommends against use during breastfeeding.

Combipatch and Climara Pro

Estrogen and progestins are contraindicated in pregnancy. Both hormones cross the placenta. Levonorgestrel and norethindrone acetate are progestins with androgenic activity that may affect fetal development. Neither patch is appropriate in any trimester.

Neither patch provides reliable contraception for perimenopausal women. The doses are far below what is needed to suppress ovulation consistently. Women in the menopausal transition who are using these patches for symptom management still need contraception if pregnancy is to be avoided. ACOG guidance on contraception in perimenopause recommends continuing contraception until 12 consecutive months of amenorrhea (consistent with the WHO Medical Eligibility Criteria definition of menopause).

Regarding lactation: systemic estrogen suppresses milk production and is not recommended postpartum in breastfeeding women.

Who This Comparison Is Right For (and Who Should Go a Different Route)

Fezolinetant Is Worth Prioritizing If You:

• Have a personal history of ER+ breast cancer or are on aromatase inhibitor therapy
• Have a documented history of DVT, pulmonary embolism, or stroke
• Want to avoid any hormonal intervention for personal or medical reasons
• Have only vasomotor symptoms (hot flashes, night sweats) and no GSM or bone-loss concerns
• Cannot tolerate oral or topical estrogen

Combination Patches (Combipatch or Climara Pro) Are Worth Prioritizing If You:

• Are under 60 and within 10 years of your last period and have no contraindications
• Have vasomotor symptoms AND genitourinary symptoms AND significant bone loss concern
• Have an intact uterus and need endometrial protection
• Have already responded well to estrogen therapy in the past
• Have elevated triglycerides that make oral hormone therapy inadvisable (the transdermal route sidesteps hepatic triglyceride stimulation)

Neither Is the Full Answer If You:

• Are perimenopausal and still need contraception (see your clinician about a hormonal IUD or low-dose combined pill with overlap)
• Have active liver disease (both carry hepatic caveats, combination patches via contraindication in severe disease and fezolinetant via its hepatotoxicity warning)
• Have severe GSM as your primary complaint (vaginal estrogen is more effective than either option for local genitourinary symptoms and carries minimal systemic absorption)

Switching From Veozah to Combipatch or Climara Pro (or Vice Versa)

No washout period is pharmacologically required when switching from fezolinetant to a transdermal patch. Fezolinetant's half-life is approximately 8 to 10 hours. It clears within a day or two. You can generally apply your first patch the morning after your last fezolinetant dose, though your clinician may prefer a brief overlap period or a direct switch based on your symptom burden.

Switching from a combination patch to fezolinetant requires more planning. Removing an estrogen patch causes estrogen levels to drop over 24 to 48 hours. Some women experience a temporary rebound in hot flash severity during this transition because the NK3R pathway has been suppressed by exogenous estrogen and takes a short time to respond to fezolinetant's mechanism. Expect a 2 to 4 week window where symptoms may feel worse before fezolinetant reaches full effect, consistent with SKYLIGHT-1 trial data showing maximal benefit emerging between weeks 4 and 12.

If the reason for switching is tolerability rather than contraindication, discuss whether a lower estrogen patch dose or a different progestin formulation might solve the problem before abandoning the hormonal route entirely.

Side-Effect Profiles Side by Side

| Side Effect | Veozah (fezolinetant) | Combipatch / Climara Pro | |---|---|---| | Hot flash relief | Yes (NK3R blockade) | Yes (estrogen replacement) | | Liver enzyme elevation | Yes, monitoring required | Rare with transdermal route | | Breast tenderness | Not reported | Common, especially early | | Irregular bleeding | Not applicable | Possible, especially in perimenopause | | Skin reaction at patch site | N/A | Yes, local irritation in 10-20% | | DVT / VTE risk | Not associated | Low with transdermal; higher with oral estrogen | | Mood / anxiety effects | Neutral to modest improvement | Estrogen improves mood; progestin may worsen in sensitive women | | GSM improvement | None | Yes | | Bone protection | None documented | Yes, estrogen preserves bone mineral density |

The Evidence Gap You Should Know About

The SKYLIGHT-1 trial enrolled 501 women with a mean age of 54 years. The trial excluded women with significant cardiovascular disease, active liver disease, or a history of cancer. This means the evidence base for fezolinetant in high-risk special populations is extrapolated from a relatively healthy, postmenopausal cohort. The combination patch trials have similarly limited representation of women with complex comorbidities.

Women have been historically excluded from cardiovascular drug trials, and menopause-specific cardiovascular subgroup analyses remain underpowered. The Menopause Society 2022 Hormone Therapy Position Statement acknowledges this directly, noting that individualization of therapy is required because no single dataset covers the full spectrum of menopausal women.

Direct head-to-head trials comparing fezolinetant with combination hormone therapy do not currently exist. Every recommendation in this article, and in clinical practice, represents a synthesis of mechanism, population subgroup data, pharmacology, and guideline extrapolation rather than a single definitive study.

A Note From the WomanRx Editorial Board

"The framing of 'hormones vs no hormones' misses the real clinical question, which is always about which mechanism best fits this woman's physiology right now. A 52-year-old with ER+ breast cancer and five hot flashes a night is not the same patient as a 48-year-old with irregular periods, vaginal dryness, and a family history of osteoporosis. Fezolinetant solved a real gap in our toolkit. But it solves exactly one problem. Transdermal combination therapy solves several at once, for the right patient." Said by Dr. Elena Vasquez, MD, WomanRx Medical Reviewer and reproductive endocrinologist, reviewing this article January 2025.